Effects of a selective cyclo-oxygenase 2 inhibitor on colonic anastomotic and skin wound integrity

British Journal of Surgery

Volumn 91, Issue 12, 2004, Pages 1613-1618

  Cahill, R A ^a   Sheehan, K M ^b   Scanlon, R W ^b   Murray, F E ^b   Kay, E W ^b   Redmond, H P ^a  

^a University College Cork and INFANT Centre   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; EOSIN; HEMATOXYLIN; ROFECOXIB; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; COLON ANASTOMOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DESCENDING COLON; DRUG EFFECT; LAPAROTOMY; MALE; MEASUREMENT; NONHUMAN; PREOPERATIVE PERIOD; PRESSURE MEASUREMENT; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SKIN INJURY; STAINING; STATISTICAL SIGNIFICANCE; SURGICAL WOUND; TENSILE STRENGTH; TENSION; TISSUE SECTION; WOUND HEALING;

ANASTOMOSIS, SURGICAL; ANIMALS; COLON; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ISOENZYMES; MALE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; WOUND HEALING;

EID: 10244235295     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4722     Document Type: Conference Paper

References (36)

1. Paganini-Hill A. Aspirin and colorectal cancer. BMJ 1993; 307: 278-279.
2. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890.
3. Huls G, Koornstra JJ, Kleibeuker JH. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 2003; 362: 230-232.
4. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclo-oxygenase may have anti-inflammatory properties. Nat Med 1999; 5: 698-701.
5. Stenson WF. Cyclooxygenase 2 and wound healing in the stomach. Gastroenterology 1997; 112: 645-648.
6. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-1847.
7. Siebert K, Lefkowith J, Tripp C, Isakson P, Needleman P. Cox-2 inhibitors - is there a cause for concern? Nat Med 1999; 5: 621-622.
8. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134-143.
9. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
10. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106-2111.
11. Gimbel JS, Brugger A, Zhao W, Verburg KM, Geis GS. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001; 23: 228-241.
12. Newberry RD, Stenson WF, Lorenz RG. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med 1999; 5: 900-906.
13. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPAR-γ. J Biol Chem 2000; 275: 28 028-28 032.
14. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The perioxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
15. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
16. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-1423.
17. Schmassmann A, Peskar BM, Stettler C, Netzer P, Stroff T, Flogerzi B et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer model in rats. Br J Pharmacol 1998; 123: 795-804.
18. Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, Smithies O et al. Impaired mucosal defence to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 2000; 105: 469-478.
19. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclo-oxygenase-2. J Clin Invest 1996; 98: 2076-2085.
20. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Mineral Res 2002; 17: 963-976.
21. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D et al. Rofecoxib (Vioxx, MK-0966; 4-(4′methylsulfonylphenyl)-3-phenyl-2(SK)- furanone: a potent and orally active cyclo-oxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999; 290: 551-560.
22. Pinto Pereira LM, Chen D, Clement Y, Simeon D. Analgesic effects of diclofenac suppository and injection after preoperative administration. Int J Clin Pharmacol Res 1999; 19: 47-51.
23. Mastboom WJ, Hendriks T, van Elteren P, de Boer HH. The influence of NSAIDs on experimental intestinal anastomoses. Dis Colon Rectum 1991; 34: 236-243.
24. de Sousa JB, Soares EG, Aprilli F. Effects of diclofenac sodium on intestinal anastomotic healing. Experimental study on the small intestine of rabbits. Dis Colon Rectum 1991; 34: 613-617.
25. Brennan SS, Foster ME, Morgan A, Leaper DJ. Prostaglandins in colonic anastomotic healing. Dis Colon Rectum 1984; 27: 723-725.
26. Bacon PA. Nonsteroidal anti-inflammatory drugs and immunologic function. Overview of the European experience. Am J Med 1984; 77: 26-31.
27. Hendriks T, Mastboom WJ. Healing of experimental intestinal anastomosis. Parameters for repair. Dis Colon Rectum 1990; 33: 891-901.
28. Rao SSC, Sadeghi P, Beaty J, Kavlock R, Ackerson K. Ambulatory 24-h colonic manometry in healthy humans. Am J Physiol Gastrointest Liver Physiol 2001; 280: G629-G639.
29. Tadros T, Wobbes T, Hendriks T. Opposite effects of interleukin-2 on normal and transfusion-suppressed healing of experimental anastomoses. Ann Surg 1993; 218: 800-808.
30. Setzen G, Williams EF III. Tissue response to suture materials implanted subcutaneously in a rabbit model. Plast Reconstr Surg 1997; 100: 1788-1795.
31. Hadley J, Malik N, Meek K. Collagen as a model system to investigate the use of aspirin as an inhibitor of protein glycation and crosslinking. Micron 2001; 32: 307-315.
32. Blomme EA, Chinn KS, Hardy MM, Casler JJ, Kim SH, Opsahl AC et al. Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br J Dermatol 2003; 148: 211-223.
33. Muscara MN, McKnight W, Asfaha S, Wallace JL. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Br J Pharmacol 2000; 129: 681-686.
34. Martens MF, Huyben CM, Hendriks T. Collagen synthesis in fibroblasts from human colon: regulatory aspects and differences with skin fibroblasts. Gut 1992; 33: 1664-1670.
35. Zushi S, Shinomura Y, Kiyohara T, Minami T, Sugimachi M, Higashimoto Y et al. Role of prostaglandins in intestinal epithelial restitution stimulated by growth factors. Am J Physiol 1996; 270: G757-G762.
36. Oxlund H, Christensen H, Seyer-Hansen M, Andreassen TT. Collagen deposition and mechanical strength of colon anastomoses and skin incisional wounds of rats. J Surg Res 1996; 66: 25-30.